As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals continues to develop therapies where there is a need. Veeva Systems has a long runway for growth in its niche of the cloud market. Equity markets have been seesawing for the ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ® Seeks to expand licensing of its proprietary CRISPR RNP technology SEOUL, South Korea, April 21, 2025 ...

$1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Unmet medical need ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...